

## Santen Announces Cancellation of Treasury Shares

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Takeshi Ito) announced that it has resolved at the Board of Directors meeting held on October 4, 2022 to cancel treasury shares as stated below, in accordance with Article 178 of the Companies Act (Japan).

- |   |   |
|---|---|
| 1. Class of shares to be canceled:        | Common shares   |
| 2. Total number of shares to be canceled: | 12,500,000 shares<br>(The ratio against total number of the outstanding shares before the Cancellation: 3.1%) |
| 3. Scheduled date of cancellation:        | October 31, 2022  |

(1) The total number of the outstanding shares of the Company (including its treasury shares) after the Cancellation is expected to be 388,208,354 shares.

(2) The number of treasury shares after the Cancellation is expected to be 302,958 shares.

### Contact:

Guillaume Sakuma  
Global Head of IR, IR Group  
E-mail: [ir@santen.com](mailto:ir@santen.com)

### **About Santen**

As a specialized company dedicated to eye health, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.

Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.

With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

For more information, please visit Santen’s website ( <https://www.santen.com/en/> ).